Concepedia

Wendy L. See

WL

10

Publications

724

Citations

10

H-Index

2002

Active since

Affiliations

Memorial Sloan Kettering Cancer Center(Current)

University of California, San Francisco

Neurological Surgery

Cornell University

The University of Texas MD Anderson Cancer Center

Wendy L. See is an author at Memorial Sloan Kettering Cancer Center specializing in medicine, cell biology, and tumor biology.

ORCID

Top concepts

Publications per year

2002–2022

10

Publications

10

Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia

Daniel A. Pollyea, Martin S. Tallman, Stéphane de Botton et al. · Leukemia · 2019 · 235 citations · Full text

Sensitivity of Glioblastomas to Clinically Available MEK Inhibitors Is Defined by Neurofibromin 1 Deficiency

Wendy L. See, I‐Li Tan, Joydeep Mukherjee et al. · Cancer Research · 2012 · 99 citations · Full text

Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial

Eytan M. Stein, Amir T. Fathi, Courtney D. DiNardo et al. · The Lancet Haematology · 2020 · 97 citations

, , +7

Mutant IDH1-Driven Cellular Transformation Increases RAD51-Mediated Homologous Recombination and Temozolomide Resistance

Shigeo Ohba, Joydeep Mukherjee, Wendy L. See et al. · Cancer Research · 2014 · 81 citations · Full text

, , +21

Hyperactivation of protein kinase B and ERK have discrete effects on survival, proliferation, and cytokine expression in Nf1-deficient myeloid cells

Shane Donovan, Wendy L. See, Jeannette M. Bonifas et al. · Cancer Cell · 2002 · 64 citations · Full text

, , +11

Rows per page

1–5 of 10